I would not call it gambling, really. Yes, investors need to do their full research and make decision that suit their appetite.
The fall in Ebita was clearly explained by delay in a project and additional spending for strategic development, obviously it was for Cognigram, with improved deployment model in general practice medicine, opening a new market.
Will Cognigram be a success? Cognigram received FDA clearance at the end of Jul. Its first commercial in USA is announced in early Oct, an impressive confirmation of CGS reputation in the field. I can only see Cognigram as the only digital disruptor to traditional practices, a niche market they can own.
Lets not forget the formidable list of pharmaceutical clients, the numbers of scientific researches and test records that CGS owns.
I would not call it gambling, really. Yes, investors need to do...
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CGS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
-0.018(1.56%) |
Mkt cap ! $191.2M | |||
| Open | High | Low | Value | Volume |
| $1.11 | $1.11 | $1.10 | $6.34K | 5.714K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1530 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 4500 | 1 |
View Market Depth
| Last trade - 11.12am 01/07/2024 (20 minute delay) ? |
| CGS (ASX) Chart |